Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]T. Renné, A. H. Schmaier, K. F. Nickel, M. Blombäck and C. Maas: In vivo roles of factor XII. Blood 120, 4296-4303 (2012)

  • [2]D. E. Cool and R. T. MacGillivray: Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5'-flanking region. J Bio Chem 262, 13662-13673 (1987)

  • [3]J. Bjorkqvist, K. F. Nickel, E. Stavrou and T. Renne: In vivo activation and functions of the protease factor XII. Thromb Haemost 112, 868-875 (2014)

  • [4]C. Maas, J. W. P. Govers-Riemslag, B. Bouma, B. Schiks, B. P. C. Hazenberg, H. M. Lokhorst, P. Hammarström, H. ten Cate, P. G. de Groot, B. N. Bouma and M. F. B. G. Gebbink: Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118, 3208-3218 (2008)

  • [5]M. Pathak, P. Wilmann, J. Awford, C. Li, B. K. Hamad, P. M. Fischer, I. Dreveny, L. V. Dekker and J. Emsley: Coagulation factor XII protease domain crystal structure. J Thromb Haemost 13, 580-591 (2015)

  • [6]H.-U. Pauer, T. Renné, B. Hemmerlein, T. Legler, S. Fritzlar, I. Adham, W. Müller-Esterl, G. Emons, U. Sancken, W. Engel and P. Burfeind: Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thrombo Haemost 92, 503-508 (2004)

  • [7]T. Renne, M. Pozgajova, S. Gruner, K. Schuh, H. U. Pauer, P. Burfeind, D. Gailani and B. Nieswandt: Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202, 271-81 (2005)

  • [8]M. Schloesser, S. Zeerleder, G. Lutze, W. M. Halbmayer, S. Hofferbert, B. Hinney, H. Koestering, B. Lammle, G. Pindur, K. Thies, M. Kohler and W. Engel: Mutations in the human factor XII gene. Blood 90, 3967-3977 (1997)

  • [9]Y. Feng, X. Ye, Y. Pang, J. Dai, X.-f. Wang and X.-h. Zhou: A novel mutation in a patient with congenital coagulation factor XII deficiency. Chin Med J 121, 1241-1244 (2008)

  • [10]E. Matsuki, Y. Miyakawa and S. Okamoto: A novel factor XII mutation, FXII R84P, causing factor XII deficiency in a patient with hereditary spastic paraplegia. Blood Co agul Fibrinolysis 22, 227-230 (2011)

  • [11]A. M. Lombardi, E. Bortoletto, P. Scarparo, M. Scapin, L. Santarossa and A. Girolami: Genetic study in patients with factor XII deficiency: a report of three new mutations exon 13 (Q501STOP), exon 14 (P547L) and -13C>T promoter region in three compound heterozygotes. Blood Coagul Fibrinolysis 19, 639-643 (2008)

  • [12]T. Miyata, S. Kawabata, S. Iwanaga, I. Takahashi, B. Alving and H. Saito: Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571----Ser substitution. Proc Natl Acad Sci U S A 86, 8319-8322 (1989)

  • [13]K. Iijima, Y. Arakawa, Y. Sugahara, M. Matsushita, Y. Moriguchi, H. Shimohiro and M. Nakagawa: Factor XII Osaka: Abnormal factor XII with partially defective prekallikrein cleavage activity. Thromb Haemost 105, 473-478 (2011)

  • [14]W. A. Wuillemin, M. Furlan, H. Stricker and B. Lammle: Functional characterization of a variant factor XII (F XII Locarno) in a cross reacting material positive F XII deficient plasma. Thromb Haemost 67, 219-225 (1992)

  • [15]T. Kanaji, S. Kanaji, K. Osaki, M. Kuroiwa, M. Sakaguchi, K. Mihara, Y. Niho and T. Okamura: Identification and characterization of two novel mutations (Q421 K and R123P) in congenital factor XII deficiency. Thromb Haemost 86, 1409-1415 (2001)

  • [16]S. Oguchi, K. Ishii, T. Moriki, E. Takeshita, M. Murata, Y. Ikeda and K. Watanabe: Factor XII Shizuoka, a novel mutation (Ala392Thr) identified and characterized in a patient with congenital coagulation factor XII deficiency. Thrombo Res 115, 191-197 (2005)

  • [17]K. J. Livak and T. D. Schmittgen: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods 25, 402-408 (2001)

  • [18]N. Enjolras, J.-L. Plantier, M.-H. Rodriguez, M. Rea, O. Attali, C. Vinciguerra and C. Negrier: Two novel mutations in EGF-like domains of human factor IX dramatically impair intracellular processing and secretion. J Thromb Haemost 2, 1143-1154 (2004)

  • [19]G. Endler, M. Exner, C. Mannhalter, S. Meier, K. Ruzicka, S. Handler, S. Panzer, O. Wagner and P. Quehenberger: A common C-->T polymorphism at nt 46 in the promoter region of coagulation factor XII is associated with decreased factor XII activity. Thrombo Res 101, 255-260 (2001)

  • [20]D. V. Kravtsov, Wenman Wu, Joost C.M.Meijers, Mao-Fu Sun, Morey A.Blinder, Thao P. Dang, Hongli Wang and David Gailani: Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood 104, 128-134 (2004)

  • [21]S. Kondo, F. Tokunaga, S. Kawano, Y. Oono, S. Kumagai and T. Koide: Factor XII Tenri, a novel cross-reacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation. Blood 93, 4300-4308 (1999)

  • [22]H. Wada, J. Nishioka, Y. Kasai, K. Kato-Nakazawa, Y. Abe, Y. Morishita, K. Nakatani and T. Nobori: Molecular characterization of coagulation factor XII deficiency in a Japanese family. Thromb Haemost 90, 59-63 (2003)

  • [23]K. Ishii, S. Oguchi, T. Moriki, Y. Yatabe, E. Takeshita, M. Murata, Y. Ikeda and K. Watanabe: Genetic analyses and expression studies identified a novel mutation (W486C) as a molecular basis of congenital coagulation factor XII deficiency. Blood Coagul Fibrinolysis 15, 367-373 (2004)

  • [24]R. R. Kopito: ER quality control: the cytoplasmic connection. Cell 88, 427-430 (1997)

  • [25]R. Sitia and I. Braakman: Quality control in the endoplasmic reticulum protein factory. Nature 426, 891-894 (2003)

  • [26]S. O. Brennan, G. Maghzal, B. L. Shneider, R. Gordon, M. S. Magid and P. M. George: Novel fibrinogen gamma375 Arg>Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 36, 652-658 (2002)

  • [27]S. Duga, R. Asselta, E. Santagostino, S. Zeinali, T. Simonic, M. Malcovati, P. M. Mannucci and M. L. Tenchini: Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood 95, 1336-1341 (2000)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Article

Novel mutations in congenital factor XII deficiency

Peipei Jin 1,3, Wenli Jiang 3, Hui Yan 1, Lanbo Liu 1, Song Gu 2, Xuefeng Wang 4, Lisong Shen 3, Xi Mo 1,*
Affiliations
Article Info

1 Key Laboratory of Pediatric Hematology & Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai, China

2 Department of Pediatric surgery, Shanghai Children’s Medical Center, Shanghai, China

3 Departments of Clinical Laboratory, Xinhua Hospital, Shanghai, China

4 Departments of Clinical Laboratory, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Abstract

Several mutations in factor XII have been reported in patients with factor XII deficiency. Here, we described three mutations in the F12 gene (c. 6635G>A (p. G259E), c. 6658G>C (p. R267G) and c. 8489G>A (p. E521K)) of five patients with congenital FXII deficiency. Among these, two were heterozygous mutations. All five patients had prolonged activated partial thromboplastin time, as well as markedly decreased FXII activity and antigen levels. In vitro studies in transiently transfected HEK 293T cells demonstrated that these mutations significantly lowered the FXII levels in the culture media, but had no impact on transcription. Further protein degradation inhibition experiments with various inhibitors suggested that the three mutants were degraded intracellularly through the proteasome pathway in the pre-Golgi compartment. Moreover, G259E and R267G mutations exhibited dominant negative effects, consistent with the phenotypes observed in the heterozygous carriers. Such dominant negative effects were not due to the dimerization of FXII. Our findings suggest that the three mutations in the F12 gene are the causing reasons for the cross-reactive material-negative FXII deficiencies.

Keywords

  • Factor XII
  • Factor XII Deficiency
  • Blood Coagulation
  • Cross-Reactive Material-Negative
  • Dominant Negative

References